Adjuvant Therapy of Osteosarcoma - A Phase II Trial: Southwest Oncology Group Study 9139

Cancer

Volumn 100, Issue 4, 2004, Pages 818-825

  Zalupski, Mark M ^a   Rankin, Cathryn ^b   Ryan, James R ^c   Lucas, David R ^c   Muler, Jeffrey ^a   Lanier, Keith S ^d   Budd, George Thomas ^e   Biermann, J Sybil ^a   Meyers, Frederick J ^f   Antman, Karen ^g  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Columbia River Comm Clin Oncol P ^*  (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adjuvant chemotherapy; Cisplatin; Doxorubicin; Ifosfamide; Osteosarcoma (OS)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BONE CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL TRIAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIMB SALVAGE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 10744233986     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20021     Document Type: Article

References (39)

1. Friedman MA, Carter SK. The therapy of osteogenic sarcoma. Current status and thoughts for future. J Surg Oncol. 1972;4:482-510.
2. Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of twenty-one. J Bone Joint Surg. 1970;52A: 411-422.
3. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
4. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
5. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
6. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342-352.
7. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Clin Orthop. 1991;270:8-14.
8. Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
9. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
10. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer. 1992;69:698-708.
11. Provisor Al, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
12. Meyers PA, Garlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-2459.
13. Rosen G, Capparros B, Huvos M, et al. Pre-operative chemotherapy for osteosarcoma: selection of postoperative adjuvant chemotherapy base on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
14. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of Stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12:1849-1858.
15. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
16. Raymond AK. Osteosarcoma: specimen management after preoperative chemotherapy and arteriogram-directed dissection. Presented at Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multidisciplinary Approach, Houston Texas, November 2-5, 1988.
17. Marti C, Kroner T, Remagen W. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115-117.
18. Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131-135.
19. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7:126-131.
20. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989;7:1208-1216.
21. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83:1460-1470.
22. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.
23. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
24. Sutow WW, Gehan EA, Dyment PG, et al. Multidrug adjuvant chemotherapy for osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treat Rep. 1978; 62:265-269.
25. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities of trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
26. Look AT, Douglass EC, Meyer WH. Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity. N Engl J Med. 1988;318:1567-1572.
27. Chan HSL, Grogan TM, Gaddad G, et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 1997;89:1706-1715.
28. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996;14:467-472.
29. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/ erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.
30. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
31. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
32. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. EurJ Cancer. 2001;37:2030-039.
33. Meyers P, Schwartz C, Bernstein M, et al. Addition of ifosfamide and nmramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event free survival (EFS) in localized osteosarcoma. Proc Am Soc Clin Oncol. 2001;20: 1463.
34. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001;19:171-182.
35. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24:87-92.
36. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911-917.
37. Cortes E, Necheles TF, Holland JF, et al. Adjuvant therapy of operable primary osteosarcoma: a Cancer and Leukemia Group B experience, In: Salmon S, Jones S, editors. Adjuvant therapy of cancer. Volume 3. New York: Grune & Stratton, 1981:201-210.
38. Krailo M, Ertel E, Makley J, et al. A randomized trial comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma. Med Pediatr Oncol. 1987;15:69-77.
39. Lewis IJ, Weeden S, Machin D, et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol. 2000;18:4028-4037.